Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCD601 (Siplizumab) for Tolerance Induction in Living Donor Renal Transplantation
NCT04803058Phase 2Terminated
- Sponsor
- ITB-MED
- Start
- Dec 2022
- Primary completion
- Feb 2026
- Countries
- 2
01
Overview
A Phase 2 trial of siplizumab in kidney transplantation, sponsored by ITB-MED. Started Dec 2022; status: terminated.
02
Drugs
siplizumab
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT04803058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04803058.